Andrade Suellen Marinho, de Oliveira Eliane Araújo, Alves Nelson Torro, Dos Santos Ana Cristina Gomes, de Mendonça Camila Teresa Ponce Leon, Sampaio Danielle Dorand Amorim, da Silva Edyllaine Elidy Querino Cavalcante, da Fonsêca Égina Karoline Gonçalves, de Almeida Rodrigues Evelyn Thais, de Lima Gabriela Nayara Siqueira, Carvalho Jamerson, da Silva Jessyca Alves Silvestre, Toledo Manuella, da Rosa Marine Raquel Diniz, Gomes Marcia Queiroz de Carvalho, de Oliveira Melquisedek Monteiro, Lemos Moema Teixeira Maia, Lima Nágylla Gomes, Inácio Penha, da Cruz Ribeiro E Rodrigues Petra Maria, Ferreira Rayssa Gabriela Dantas, Cavalcante Renata, de Brito Aranha Renata Emanuela Lyra, Neves Regina, da Costa E Souza Rodrigo Marmo, Portugal Thainá Magalhães, Martins Wanessa Kallyne Nascimento, Pontes Vivian, de Paiva Fernandes Thiago Monteiro, Contador Israel, Fernández-Calvo Bernardino
Department of Physiotherapy, The Federal University of Paraíba, João Pessoa, Brazil.
Department of Psychology, The Federal University of Paraíba, João Pessoa, Brazil.
Front Aging Neurosci. 2018 Nov 2;10:334. doi: 10.3389/fnagi.2018.00334. eCollection 2018.
Despite advances in the treatment of Alzheimer's disease (AD), there is currently no prospect of a cure, and evidence shows that multifactorial interventions can benefit patients. A promising therapeutic alternative is the use of transcranial direct current stimulation (tDCS) simultaneously with cognitive intervention. The combination of these non-pharmacological techniques is apparently a safe and accessible approach. This study protocol aims to compare the efficacy of tDCS and cognitive intervention in a double-blind, randomized and factorial clinical trial. One hundred participants diagnosed with mild-stage AD will be randomized to receive both tDCS and cognitive intervention, tDCS, cognitive intervention, or placebo. The treatment will last 8 weeks, with a 12-month follow-up. The primary outcome will be the improvement of global cognitive functions, evaluated by the AD Assessment Scale, cognitive subscale (ADAS-Cog). The secondary outcomes will include measures of functional, affective, and behavioral components, as well as a neurophysiological marker (Brain-derived neurotrophic factor, BDNF). This study will enable us to assess, both in the short and long term, whether tDCS is more effective than the placebo and to examine the effects of combined therapy (tDCS and cognitive intervention) and isolated treatments (tDCS vs. cognitive intervention) on patients with AD. : www.ClinicalTrials.gov, identifier NCT02772185-May 5, 2016.
尽管阿尔茨海默病(AD)的治疗取得了进展,但目前尚无治愈的前景,且有证据表明多因素干预对患者有益。一种有前景的治疗选择是将经颅直流电刺激(tDCS)与认知干预同时使用。这些非药物技术的结合显然是一种安全且可及的方法。本研究方案旨在通过一项双盲、随机和析因临床试验比较tDCS和认知干预的疗效。100名被诊断为轻度AD的参与者将被随机分组,分别接受tDCS与认知干预、tDCS、认知干预或安慰剂治疗。治疗将持续8周,并进行12个月的随访。主要结局将是通过AD评估量表认知子量表(ADAS-Cog)评估的整体认知功能的改善。次要结局将包括功能、情感和行为成分的测量,以及一种神经生理学标志物(脑源性神经营养因子,BDNF)。本研究将使我们能够在短期和长期内评估tDCS是否比安慰剂更有效,并研究联合治疗(tDCS与认知干预)和单独治疗(tDCS与认知干预)对AD患者的影响。:www.ClinicalTrials.gov,标识符NCT02772185 - 2016年5月5日。